glp 1 pipeline GLP-1 Agonists Drug Analysis Report 2025 What's next for GLP-1 innovation:

GC30783 AZD5904 AZD5904 is a selective and irreversible inhibitor of human Myeloperoxidase (MPO) with an IC50 of 140 nM and has similar potency in mouse and rat

Macular perfusion alterations in people with recent-onset diabetes and novel diabetes subtypes

The response to Tirzepatide can differ between patients, and it may not lead to significant weight loss in some cases

That kind of systemic reach challenges how we define healingand how we build care around it

But those options are still in trials

Dikomo Shungu at Weill Cornell utilized proton magnetic resonance spectroscopy (1H MRS) to look directly inside the brains of ME/CFS patients